William Pickering, an analyst from Bernstein, reiterated the Buy rating on Beam Therapeutics (BEAM – Research Report). The associated price target remains the same with $37.00.
William Pickering has given his Buy rating due to a combination of factors including the promising data from Beam Therapeutics’ AATD Phase 1 study, which was described as extremely impressive by an expert in the field. Despite the small sample size, the data suggests significant potential, with the possibility of achieving higher post-infusion AAT levels in heavier patients, which could lead to slower disease progression.
Additionally, there is an expectation of positive outcomes from future lung and liver data, which could provide further insights into the company’s gene editing capabilities. While there is some regulatory uncertainty, the overall outlook remains optimistic, particularly with the potential for new data to enhance the commercial product profile. This combination of scientific promise and future data potential underpins Pickering’s Buy rating on BEAM stock.
In another report released on March 21, Wells Fargo also maintained a Buy rating on the stock with a $75.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com